Do analysts rate OCS or MOR?

Oculis currently has a consensus target price of $38.00, suggesting a potential upside of 214.31%. Given Oculis' stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, OCS or MOR?

Oculis has higher earnings, but lower revenue than MorphoSys. Oculis is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis N/A N/A -$119.44M -$1.74 N/A MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A

Is OCS or MOR more profitable?

MorphoSys has a net margin of -226.79% compared to Oculis' net margin of -6,777.18%. Oculis' return on equity of -42.61% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -6,777.18% -42.61% -35.23% MorphoSys -226.79% -694.31% -22.55%

Is ATAI or OCS more profitable?

Oculis has a net margin of -6,777.18% compared to Atai Beckley's net margin of -14,938.36%. Oculis' return on equity of -42.61% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Atai Beckley -14,938.36% -88.30% -58.88% Oculis -6,777.18% -42.61% -35.23%

Do analysts prefer OCS or RGC?

Oculis presently has a consensus target price of $38.00, suggesting a potential upside of 214.31%. Given Oculis' stronger consensus rating and higher probable upside, equities analysts plainly believe Oculis is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, OCS or RGC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis N/A N/A -$119.44M -$1.74 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media refer more to OCS or RGC?

In the previous week, Oculis and Oculis both had 1 articles in the media. Oculis' average media sentiment score of 1.40 beat Regencell Bioscience's score of 0.00 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor OCS or SUPN?

In the previous week, Supernus Pharmaceuticals had 7 more articles in the media than Oculis. MarketBeat recorded 8 mentions for Supernus Pharmaceuticals and 1 mentions for Oculis. Oculis' average media sentiment score of 1.40 beat Supernus Pharmaceuticals' score of 1.16 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, OCS or TRVI?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis N/A N/A -$119.44M -$1.74 N/A Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A

Is OCS or TRVI more profitable?

Trevi Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Trevi Therapeutics' return on equity of -23.59% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -6,777.18% -42.61% -35.23% Trevi Therapeutics N/A -23.59% -22.64%

Does the media favor OCS or TRVI?

In the previous week, Trevi Therapeutics had 6 more articles in the media than Oculis. MarketBeat recorded 7 mentions for Trevi Therapeutics and 1 mentions for Oculis. Oculis' average media sentiment score of 1.40 beat Trevi Therapeutics' score of 1.34 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oculis (OCS) Competitors

$12.09 +0.07 (+0.58%)

As of 03:38 PM Eastern

Compare

OCS vs. MOR, ATAI, RGC, SUPN, and TRVI

Should you buy Oculis stock or one of its competitors? Oculis's main competitors and comparable companies include MorphoSys (MOR), Atai Beckley (ATAI), Regencell Bioscience (RGC), Supernus Pharmaceuticals (SUPN), and Trevi Therapeutics (TRVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Oculis compare to MorphoSys?

Oculis (NASDAQ:OCS) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Oculis currently has a consensus target price of $38.00, suggesting a potential upside of 214.31%. Given Oculis' stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Oculis had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for Oculis and 0 mentions for MorphoSys. Oculis' average media sentiment score of 1.40 beat MorphoSys' score of 0.00 indicating that Oculis is being referred to more favorably in the media.

Company	Overall Sentiment
Oculis	Positive
MorphoSys	Neutral

MorphoSys has a net margin of -226.79% compared to Oculis' net margin of -6,777.18%. Oculis' return on equity of -42.61% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
MorphoSys	-226.79%	-694.31%	-22.55%

Oculis has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

22.3% of Oculis shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Oculis has higher earnings, but lower revenue than MorphoSys. Oculis is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	N/A	N/A	-$119.44M	-$1.74	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Summary

Oculis beats MorphoSys on 9 of the 15 factors compared between the two stocks.

How does Oculis compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Oculis (NASDAQ:OCS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Oculis has lower revenue, but higher earnings than Atai Beckley. Oculis is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.47M	610.37	-$660.05M	-$2.18	N/A
Oculis	N/A	N/A	-$119.44M	-$1.74	N/A

Atai Beckley presently has a consensus target price of $10.56, suggesting a potential upside of 43.43%. Oculis has a consensus target price of $38.00, suggesting a potential upside of 214.31%. Given Oculis' stronger consensus rating and higher probable upside, analysts plainly believe Oculis is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Atai Beckley has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, Oculis has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Oculis had 1 more articles in the media than Atai Beckley. MarketBeat recorded 1 mentions for Oculis and 0 mentions for Atai Beckley. Oculis' average media sentiment score of 1.40 beat Atai Beckley's score of 0.00 indicating that Oculis is being referred to more favorably in the news media.

Company	Overall Sentiment
Atai Beckley	Neutral
Oculis	Positive

Oculis has a net margin of -6,777.18% compared to Atai Beckley's net margin of -14,938.36%. Oculis' return on equity of -42.61% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Oculis	-6,777.18%	-42.61%	-35.23%

Summary

Oculis beats Atai Beckley on 10 of the 16 factors compared between the two stocks.

How does Oculis compare to Regencell Bioscience?

Oculis (NASDAQ:OCS) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	N/A	N/A	-$119.44M	-$1.74	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

22.3% of Oculis shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Oculis and Oculis both had 1 articles in the media. Oculis' average media sentiment score of 1.40 beat Regencell Bioscience's score of 0.00 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oculis has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

Regencell Bioscience has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Regencell Bioscience's return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
Regencell Bioscience	N/A	N/A	N/A

Oculis presently has a consensus target price of $38.00, suggesting a potential upside of 214.31%. Given Oculis' stronger consensus rating and higher probable upside, equities analysts plainly believe Oculis is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Regencell Bioscience beats Oculis on 6 of the 11 factors compared between the two stocks.

How does Oculis compare to Supernus Pharmaceuticals?

Oculis (NASDAQ:OCS) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

Supernus Pharmaceuticals has higher revenue and earnings than Oculis. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	N/A	N/A	-$119.44M	-$1.74	N/A
Supernus Pharmaceuticals	$718.95M	3.54	-$38.55M	-$1.92	N/A

Oculis has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Oculis currently has a consensus target price of $38.00, indicating a potential upside of 214.31%. Supernus Pharmaceuticals has a consensus target price of $62.83, indicating a potential upside of 43.65%. Given Oculis' stronger consensus rating and higher probable upside, analysts plainly believe Oculis is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Supernus Pharmaceuticals had 7 more articles in the media than Oculis. MarketBeat recorded 8 mentions for Supernus Pharmaceuticals and 1 mentions for Oculis. Oculis' average media sentiment score of 1.40 beat Supernus Pharmaceuticals' score of 1.16 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.3% of Oculis shares are held by institutional investors. 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Supernus Pharmaceuticals has a net margin of -13.23% compared to Oculis' net margin of -6,777.18%. Supernus Pharmaceuticals' return on equity of 11.13% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Summary

Supernus Pharmaceuticals beats Oculis on 9 of the 16 factors compared between the two stocks.

How does Oculis compare to Trevi Therapeutics?

Oculis (NASDAQ:OCS) and Trevi Therapeutics (NASDAQ:TRVI) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Trevi Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Trevi Therapeutics' return on equity of -23.59% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
Trevi Therapeutics	N/A	-23.59%	-22.64%

Oculis has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

22.3% of Oculis shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Trevi Therapeutics had 6 more articles in the media than Oculis. MarketBeat recorded 7 mentions for Trevi Therapeutics and 1 mentions for Oculis. Oculis' average media sentiment score of 1.40 beat Trevi Therapeutics' score of 1.34 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oculis currently has a consensus target price of $38.00, indicating a potential upside of 214.31%. Trevi Therapeutics has a consensus target price of $27.08, indicating a potential upside of 59.60%. Given Oculis' higher probable upside, equities research analysts plainly believe Oculis is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	N/A	N/A	-$119.44M	-$1.74	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

Summary

Trevi Therapeutics beats Oculis on 12 of the 15 factors compared between the two stocks.

Get Oculis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCS vs. The Competition

Export

Metric	Oculis	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$701.03M	$12.30B	$7.25B	$12.92B
Dividend Yield	N/A	2.60%	2.53%	8.56%
P/E Ratio	-6.95	789.77	273.84	25.43
Price / Sales	N/A	956.14	675.54	123.68
Price / Cash	N/A	92.66	76.98	52.08
Price / Book	2.52	12.42	12.90	6.17
Net Income	-$119.44M	$2.83B	$3.48B	$349.24M
7 Day Performance	-2.74%	2.26%	-0.42%	-1.46%
1 Month Performance	1.68%	5.06%	6.41%	2.47%
1 Year Performance	-26.10%	9.28%	24.92%	15.80%

Oculis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCS Oculis	2.8122 of 5 stars	$12.09 +0.6%	$38.00 +214.3%	-25.6%	$701.03M	N/A	N/A	2
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
ATAI Atai Beckley	2.8443 of 5 stars	$7.42 +0.5%	$10.56 +42.4%	+60.1%	$2.75B	$4.47M	N/A	80
RGC Regencell Bioscience	0.062 of 5 stars	$5.44 +2.8%	N/A	-50.9%	$2.73B	N/A	N/A	10	News Coverage
SUPN Supernus Pharmaceuticals	4.5211 of 5 stars	$45.27 +0.4%	$62.83 +38.8%	-1.1%	$2.63B	$718.95M	N/A	580	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCS) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oculis (OCS) Competitors

OCS vs. MOR, ATAI, RGC, SUPN, and TRVI

How does Oculis compare to MorphoSys?

Summary

How does Oculis compare to Atai Beckley?

Summary

How does Oculis compare to Regencell Bioscience?

Summary

How does Oculis compare to Supernus Pharmaceuticals?

Summary

How does Oculis compare to Trevi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS vs. The Competition

Oculis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oculis (OCS) Competitors

OCS vs. MOR, ATAI, RGC, SUPN, and TRVI

How does Oculis compare to MorphoSys?

Do analysts rate OCS or MOR?

Does the media favor OCS or MOR?

Is OCS or MOR more profitable?

Which has more risk & volatility, OCS or MOR?

Do insiders and institutionals have more ownership in OCS or MOR?

Which has higher earnings and valuation, OCS or MOR?

Summary

How does Oculis compare to Atai Beckley?

Which has stronger earnings & valuation, ATAI or OCS?

Do analysts rate ATAI or OCS?

Which has more volatility & risk, ATAI or OCS?

Do insiders & institutionals hold more shares of ATAI or OCS?

Does the media prefer ATAI or OCS?

Is ATAI or OCS more profitable?

Summary

How does Oculis compare to Regencell Bioscience?

Which has better earnings & valuation, OCS or RGC?

Do institutionals and insiders have more ownership in OCS or RGC?

Does the media refer more to OCS or RGC?

Which has more risk & volatility, OCS or RGC?

Is OCS or RGC more profitable?

Do analysts prefer OCS or RGC?

Summary

How does Oculis compare to Supernus Pharmaceuticals?

Which has higher earnings and valuation, OCS or SUPN?

Which has more volatility and risk, OCS or SUPN?

Do analysts rate OCS or SUPN?

Does the media favor OCS or SUPN?

Do institutionals and insiders believe in OCS or SUPN?

Is OCS or SUPN more profitable?

Summary

How does Oculis compare to Trevi Therapeutics?

Is OCS or TRVI more profitable?

Which has more risk and volatility, OCS or TRVI?

Do insiders & institutionals believe in OCS or TRVI?

Does the media favor OCS or TRVI?

Do analysts rate OCS or TRVI?

Which has stronger earnings & valuation, OCS or TRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS vs. The Competition

Oculis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools